Ixazomib(MLN2238)
产品编号: DC5086
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.
| Cas No.: |
1072833-77-2 |
| 名称: |
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid |
| 别名: |
MLN-2238; MLN 2238; MLN2238. |
| SMILES: |
CC(C)C[C@@H](B(O)O)NC(CNC(C1=CC(Cl)=CC=C1Cl)=O)=O |
| 分子式: |
C14H19BCl2N2O4 |
| 分子量: |
361.03 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
MLN-2238 is the biologically active Form of MLN9708. MLN2238 has an improved pharmacodynamic profile and antitumor activity compared with bortezomib in both OCI-Ly10 and PHTX22L models. Although both MLN2238 and bortezomib prolonged overall survival, red |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
| TITLE |
DOWNLOAD |
| MSDS_3387_DC5086_1072833-77-2 |
|
COA
| LOT NO. |
DOWNLOAD |
|
|
询盘
